Indication intelligence, analysis and sector perception

RMi Research Note: Fanning the faith

October 26, 2025 5:57pm

A sector catalyst

Novartis NVS) has agreed to buy Avidity Biosciences (RNA closed up Friday +$0.60 or +1.24% to $49.15) for about $12 billion.

NVS will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Friday closing price.

Avidity Biosciences is a biopharmaceutical company. RNA is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). These AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies.

The Bottom Line:

RNA's advancing and expanding pipeline has 3 programs in clinical development.

The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global P3 HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1.
The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD).
The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.

However, the acquisition by NVSs of RNA is subject to the completion of a spin-off or a sale of SpinCo and other customary closing conditions, including the receipt of regulatory approvals and the approval of Avidity stockholders.

The deal is expected to close in the 1H/26, after RNA spins out parts of its business, including its early-stage precision cardiology programs.

Also, the ticker symbol "RNA"will be worth a very pretty dollar

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 59 min ago
RMi Research Note: Fanning the faith

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.